title: Selective regulation of chemotactic lymphokine production. I. Selective potentiation of eosinophil chemotactic lymphokine production in alum hydroxy gel- and Bordetella pertussis vaccine-treated guinea pigs.
abstract: Delayed tissue eosinophilia in DNP-ovalbumin-induced allergic inflammatory skin lesions of guinea pigs was markedly enhanced by previous treatment with alum hydroxy gel (Alum) or Bordetella pertussis vaccine. This enhancement seemed due to increased production of a lymphocyte-derived eosinophil chemotactic factor (ECF) at the skin site. Treatment of animals with Alum potentiated antigen-induced in vitro ECF production by lymphoid cells from spleen and mesenteric lymph node of sensitized animals. The co-culture supernatants of lymphoid cells from Alum-treated animals also potentiated concanavalin A (Con A)-induced in vitro ECF production. The potentiating effect of Alum on ECF production seemed to be ascribed to the release of soluble factors from macrophages of the Alum-treated animals. The macrophage-derived soluble factor ECF-potentiating factor (ECF-PF) selectively potentiated ECF production but not macrophage chemotactic lymphokine production by Con A-stimulated lymphoid cells from normal animals. ECF-PF activity was associated with two separate m.w. fractions: one was 50,000 to 70,000 and the other was 10,000 to 20,000. The present study provides one of the explanations for enhanced ECF production by adjuvants, such as Alum and Bordetella pertussis vaccine.
authors.forename: K
authors.initials: K
authors.lastname: Sakata
authors.forename: K
authors.initials: K
authors.lastname: Tashiro
authors.forename: M
authors.initials: M
authors.lastname: Hirashima
authors.forename: H
authors.initials: H
authors.lastname: Hayashi
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000536:Aluminum Hydroxide / Q000008:administration & dosage*; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D001886:Bordetella pertussis / Q000276:immunology*; D002474:Cell-Free System; D002630:Chemotactic Factors / Q000096:biosynthesis*; D002631:Chemotactic Factors, Eosinophil / Q000096:biosynthesis*; D003208:Concanavalin A / Q000494:pharmacology; D004802:Eosinophilia / Q000276:immunology; D006168:Guinea Pigs; D007163:Immunosorbent Techniques; D008214:Lymphocytes / Q000378:metabolism; D008222:Lymphokines / Q000096:biosynthesis*; D008264:Macrophages / Q000378:metabolism; D008297:Male; D008970:Molecular Weight; D010323:Passive Cutaneous Anaphylaxis
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D002630:Chemotactic Factors; D002631:Chemotactic Factors, Eosinophil; D008222:Lymphokines; C022227:eosinophil stimulating promoter; D003208:Concanavalin A; C025173:basic aluminum carbonate gel; D000536:Aluminum Hydroxide